The U.S. Food and Drug Administration approved generic versions of the best-selling blood thining drug Plavix on Thursday. More
TEVA
Recent Articles
Watson Pharmaceuticals Is No Ordinary Generic
Watson Pharmaceuticals is an outstanding company that grows earnings and revenues every year in the tough generic pharma space. Consider this a top buy. More
Got Nerve? Israel Has Plenty to Offer
A resilient economy and a focus on innovation are strong lures. And more Israel-based companies are listed on the Nasdaq than any other country except the U.S. More
Why Investors Needn’t Fear the ‘Patent Cliff’
Expiring drug patents can cost pharma stocks billions of dollars, but companies and investors alike can prepare themselves well in advance. More
3 High-Yield Dividend Stocks to Avoid
Don't be tempted by the juicy payouts offered by these three well-known names. Those big dividends mask a lot of bigger problems. More
2 Stocks to Watch for the Earnings Junkies
Canadian oil extractor Cenovus and international pharmaceutical company Teva announced positive earnings reports lately. See how they each stack up. More
If Novartis’ MS Drug Falters, Biogen Will Gain
After the deaths of 11 people who were taking the drug, concerns that Gilenya may cause heart problems has hit NVS hard, ending the stock's months-long upswing. More
